Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres

Life Sciences

Volumn 124, Issue , 2015, Pages 136-143

  Yu, Xin ^a   Yao, Jun Yi ^a   He, Jie ^b   Tian, Jing Wei ^a,b  

^a YANTAI UNIVERSITY   (China)

^b State Key Laboratory of Long acting and Targeting Drug Delivery Technologies   (China)

Author keywords

Continuous dopaminergic stimulation; Neuroprotection; Parkinson's disease; Rotigotine loaded microspheres

Indexed keywords

GLUTATHIONE PEROXIDASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROSPHERE; PROTEIN BAX; PROTEIN BCL 2; ROTIGOTINE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; CYTOKINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; MICROGLIA; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MPTP POISONING; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY;

MUS;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CORPUS STRIATUM; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; MICROSPHERES; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84923326884     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2015.01.014     Document Type: Article

References (39)

1. D. Blum-Degen, T. Müller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neurosci. Lett. 202 1-2 1995 17 20
2. D. Blum, S. Torch, N. Lambeng, M. Nissou, A.L. Benabid, R. Sadoul, and J.M. Verna Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Prog. Neurobiol. 65 2 2001 135 172
3. H. Braak, T.K. Del, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2 2003 197 211
4. L. Chen, D.M. Togasaki, J.W. Langston, D.A. Di Monte, and M. Quik Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA treated dyskinetic monkeys Neuroscience 132 2 2005 409 420
5. Y.C. Chung, S.R. Kim, J.Y. Park, E.S. Chung, K.W. Park, S.Y. Won, E. Bok, M. Jin, E.S. Park, S.H. Yoon, H.W. Ko, Y.S. Kim, and B.K. Jin Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation Neuropharmacology 60 6 2011 963 974
6. L.M. Collins, A. Toulouse, T.J. Connor, and Y.M. Nolan Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease Neuropharmacology 62 7 2012 2154 2168
7. R. Dringen Metabolism and functions of glutathione in brain Prog. Neurobiol. 62 2000 649 671
8. B.A. Freeman, and J.D. Crapo Biology of disease: free radicals and tissue injury Lab. Investig. 47 1982 412 426
9. S. Gandhi, and N.W. Wood Molecular pathogenesis of Parkinson's disease Hum. Mol. Genet. 14 18 2005 2749 2755
10. H.M. Gao, P.T. Kotzbauer, K. Uryu, S. Leight, J.Q. Trojanowski, and V.M. Lee Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration J. Neurosci. 28 30 2008 7687 7698
11. A. Hald, and J. Lotharius Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol. 193 2005 279 290 (PubMed: 15869932)
12. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 4 2009 382 397
13. P. Jenner Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation Neurology 62 1 Suppl. 1 2004 S47 S55
14. C. Larramendy, I.R.E. Taravini, M.D. Saborido, J.E. Ferrario, M.G. Murer, and O.S. Gershanik Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of Parkinsonism Behav. Brain Res. 194 1 2008 44 51
15. J.M. Lee, D.S. Hwang, H.G. Kim, C.H. Lee, and M.S. Oh Dangguijakyak-san protects dopamine neurons against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity under postmenopausal conditions J. Ethnopharmacol. 139 3 2012 883 888
16. L.M. Freed Rotigotine pharmacology/toxicology 2006 Review Food And Drug Administration (application number 21829)
17. K.A. Maguire-Zeiss, D.W. Short, and H.J. Federoff Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Mol. Brain Res. 134 1 2005 18 23
18. M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients Neurosci. Lett. 180 2 1994 147 150
19. M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease Neurosci. Lett. 211 1 1996 13 16
20. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1-2 1994 208 210
21. M. Moon, H.G. Kim, L. Hwang, J.H. Seo, S. Kim, S. Hwang, S. Kim, D. Lee, H. Chung, M.S. Oh, K.T. Lee, and S. Park Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation Neurotox. Res. 15 4 2009 332 347
22. D. Nyholm, A.I. Nilsson Remahl, N. Dizdar, R. Constantinescu, B. Holmberg, R. Jansson, S.M. Aquilonius, and H. Askmark Duodenal levodopa infusion monotherapy vs. oral polypharmacy in advanced Parkinson disease Neurology 64 2 2005 216 223
23. C.W. Olanow The scientific basis for the current treatment of Parkinson's disease Annu. Rev. Med. 55 2004 41 60
24. C. Perier, K. Tieu, C. Guegan, C. Caspersen, V. Jackson-Lewis, V. Carelli, A. Martinuzzi, M. Hirano, S. Przedborski, and M. Vila Proc. Natl. Acad. Sci. 102 2005 19126 19131
25. L.J. Peterson, and P.M. Flood Oxidative stress and microglial cells in Parkinson's disease Mediat. Inflamm. 2012 2012 401264
26. A.H. Rajput, M.E. Fenton, S. Birdi, R. Macaulay, D. George, B. Rozdilsky, L.C. Ang, A. Senthilselvan, and O. Hornykiewicz Clinical-pathological study of levodopa complications Mov. Disord. 17 2 2002 289 296
27. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa N. Engl. J. Med. 342 20 2000 1484 1491
28. M. Reale, C. Iarlori, A. Thomas, D. Gambi, B. Perfetti, M. Di Nicola, and M. Onofrj Peripheral cytokines profile in Parkinson's disease Brain Behav. Immun. 23 1 2009 55 63
29. S.R. Sankar, T. Manivasagam, A. Krishnamurti, and M. Ramanathan The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables Cell. Mol. Biol. Lett. 12 4 2007 473 481
30. D. Scheller, C. Stichel-Gunkel, H. Lübbert, G. Porras, P. Ravenscroft, M. Hill, and E. Bezard Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease Neurosci. Lett. 432 1 2008 30 34
31. M. Steiger Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease Eur. J. Neurol. 15 1 2008 6 15
32. A. Wang, L. Wang, K. Sun, W. Liu, C. Sha, and Y. Li Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats Pharm. Res. 29 9 2012 2367 2376
33. V.P. Whittaker Thirty years of synaptosome research J. Neurocytol. 22 9 1993 735 742
34. M.G. Tansey, and M.S. Goldberg Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention Neurobiol. Dis. 37 3 2010 510 518
35. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 8 2007 963 976
36. D.K. Choi, S. Pennathur, C. Perier, K. Tieu, P. Teismann, D.C. Wu, V. Jackson-Lewis, M. Vila, J.P. Vonsattel, J.W. Heinecke, and S. Przedborski Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice J. Neurosci. 25 28 2005 6594-600
37. F. Jin, Q. Wu, Y.F. Lu, Q.H. Gong, and J.S. Shi Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats Eur. J. Pharmacol. 600 1-3 2008 78 82
38. V. Jackson-Lewis, J. Blesa, and S. Przedborski Animal models of Parkinson's disease Parkinsonism. Relat. Disord. 18 Suppl 1 2012 S183 S185
39. D.C. Wu, P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, and S. Przedborski NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease Proc. Natl. Acad. Sci U S A. 100 10 2003 6145 6150